Innovative retargeted oncolytic herpesvirus against nectin4-positive cancers.

Front Mol Biosci · 2023 · PMC10213976 · PMID 37251078

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

The reduction in tumor size at day 21 was highly significant for the two higher doses ( Figure 5F ).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.